Tech on Drugs with Shai Shen-Orr

In this special episode, we are sharing a conversation from the NVIDIA AI Podcast, hosted by Noah Kravitz, featuring our host Shai Shen-Orr. The discussion dives into CytoReason’s partnership with NVIDIA and how computational disease models turn massive biological data into actionable insights for faster, smarter drug development. Shai and Noah discuss: Why biology is a deep data problem with too...

What happens when two leading computational biologists swap code and models for a lively conversation? Fabian Theis, a pioneer in single-cell and AI-driven biomedical research, joins Shai for a fascinating exchange about: — The single-cell revolution and how it’s reshaping the industry. — The promise (and hype) of foundational models. — And why tomorrow’s R&D lab might be a “virtual biotech” —...

We’re kicking off Season 3 of Tech on Drugs with Prof. Nir Hacohen — Director of the Center for Cancer Research at MGH, founding director of the Broad Institute’s Cell Circuits Program, and a distinguished member of CytoReason's Science Advisory Board. Shai and Nir cover everything from the rise of antibodies and the promise (and pitfalls) of STING agonists, to the future of personalized cancer va...

Tom Bumol's career spans major roles at Eli Lilly, the Allen Institute, and beyond. He is also a distinguished member of CytoReason's Science Advisory Board. In this episode, Tom shares insights into drug development's successes, failures, and future direction, including: Lessons from lupus -  the story of a failed lupus trial that revealed the critical importance of understanding disease heteroge...

This episode was recorded in the beautiful Island of Crete, at CytoReason's employee conference, the CytoSummit. CytoReason's Co-founder Shai Shen-Orr hosts AION Labs CTO Yair Benita.  Yair is a computational biologist who spent more than 20 years studying biology through omics and clinical data in an effort to piece together mechanisms of human disease. He’s been leading computational teams in dr...

While most neuroimmunologists try to understand how the immune system affects the brain, Prof. Asya Rolls has taken the road less traveled in her lab at the Technion. She and her team try to understand how the brain affects the immune system.  In this episode of Tech on Drugs, Asya and Shai talked about the power of placebo and how brain activity, particularly in the reward system, can influence t...

This one was fun. In the latest episode of Tech on Drugs, Shai met with Prof. Eran Segal from the Weizmann Institute of Science. Eran heads a multidisciplinary team of computational biologists and experimental scientists working in the area of Computational and Systems biology. His lab at Weizmann aims to develop personalized nutrition and personalized medicine using machine learning, computationa...

Our guest this time was Prof. Ido Amit, whose lab at the Weizmann Institute of Science pioneered single cell transcriptomic analysis and its application to the immune system. Amit’s research focuses on some of the most important questions in immunology – specifically those relevant to novel targets for immunotherapy in autoimmune diseases, neurodegeneration, and cancer. A fascinating discussion be...

What will the future of precision medicine look like 5-10 years down the line? And how will AI accelerate this future? I asked Dr. Emanuele de Rinaldis to answer this and many other questions. Emanuele is VP, Global Head of Precision Medicine & Computational Biology at Sanofi R&D. He believes that AI will help us define new taxonomies of diseases. We will identify different types of Asthma...

Our guest this time is serial biotech entrepreneur Yanay Ofran. Yanay is a renowned computational biophysicist and the CEO and Co-founder of Biolojic Design. More importantly, Yanay, together with his stellar team, developed the first AI-designed antibody. He shared with Shai his (strong) opinions about: The barriers to precision medicine (and how to overcome them). The potential of AI-designed an...

The doctor in the clinic must build on molecular features and the bioinformatician in the lab must build on data from the clinic. Prof. Yehuda Chowers, a leading gastroenterologist, has been harping on this point for years. It's a two-way street that will benefit both drug makers and drug consumers. In this episode of TOD, Chowers talks to host Shai Shen-Orr about immunogenicity, clinical trials,...

Our first episode features world renowned epidemiologist, Prof. Ran Balicer , Chief Innovation Officer at Clalit Health Services, Israel’s largest healthcare organization. We talked about the mining of real-world data and how it guides healthcare policy. The impact on Covid is pretty mind-boggling!

This is a podcast about the future of pharma. From novel targets to novel biomarkers. From disease models to population models. From clinical trials to synthetic trials. In each episode, our host Prof. Shai Shen-Orr talks to world-leading scientists and healthcare executives about the future of pharma.